June 2 (Reuters) – Abivax shares tumbled 26% on Tuesday after the French biotech company unveiled the highly anticipated results of the late-stage trial for its inflammatory bowel drug the night
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)